Long-term real-world outcomes of mepolizumab and benralizumab among biologic-naïve patients with severe eosinophilic asthma: experience of three years’ therapy

Fyles, Fred, Nuttall, Amy, Joplin, Hannah and Burhan, Hassan (2023) 'Long-term real-world outcomes of mepolizumab and benralizumab among biologic-naïve patients with severe eosinophilic asthma: experience of three years’ therapy'. The Journal of Allergy and Clinical Immunology: In Practice, Vol 11, Issue 9, pp. 2715-2723.

Text Long term outcomes of biological therapy V6.0 - TRACKED.docx - Accepted Version Restricted to Repository staff only until 26 May 2024. Available under License Creative Commons Attribution Non-commercial No Derivatives. Download (66kB)

Abstract

Background
Biological therapies, such as mepolizumab and benralizumab, offer treatment options for severe eosinophilic asthma (SEA), although long-term real-world data on their use are limited.

Objective
Evaluate the impact of benralizumab/mepolizumab treatment among biologic-naïve patients with SEA over 36 months Describe the incidence of super-response at 12 and 36 months, identifying potential predictive factors.

Methods
Retrospective, single-centre study of patients with SEA started on mepolizumab/benralizumab from May 2017–December 2019 who completed 36 months of therapy. Baseline demographics , co-morbidities, and medication use were described. Clinical outcomes, including maintenance oral corticosteroid (mOCS) use, annual exacerbation rate (AER), mini Asthma Quality of Life Questionnaire (mAQLQ), Asthma Control Questionnaire (ACQ-6), and eosinophil count (EC), were collected at baseline, 12 months, and 36 months. Super-response was evaluated at 12 and 36 months.

Results
81 patients were included. mOCS use significantly improved from baseline (5.3mg/day) to 12 months (2.4mg/day, p<0.0001) and 36 months (0.6mg/day, p<0.0001). AER reduced from baseline (5.8) to 12 months (0.9, p<0.0001) and 36 months (1.2, p<0.0001). mAQLQ, ACQ-6, and EC significantly improved from baseline to 12 and 36 months. 29 patients demonstrated super-response at 12 months; compared to those without super-response these patients had better baseline AER (4.7 v 6.5, p=0.009), mAQLQ (3.41 v 2.54, p=0.002), and ACQ-6 (3.38 v 4.06, p=0.03). The majority maintained super-response to 36 months.

Conclusion
Mepolizumab and benralizumab are associated with significant improvements in OCS use, AER, and asthma control in real-world cohorts for up to 36 months, providing insight into long-term use for SEA.

Item Type:	Article
Subjects:	WF Respiratory System > Lungs > WF 600 Lungs
Faculty: Department:	Clinical Sciences & International Health > Clinical Sciences Department
Digital Object Identifer (DOI):	https://doi.org/10.1016/j.jaip.2023.05.025
SWORD Depositor:	JISC Pubrouter
Depositing User:	JISC Pubrouter
Date Deposited:	03 Jul 2023 08:51
Last Modified:	10 Oct 2023 13:13
URI:	https://archive.lstmed.ac.uk/id/eprint/22563

Statistics

View details

Actions (login required)

Edit Item